[background image] image of a healthcare professional using ai software (for an ai healthcare company)
image of pharmacist consulting with a customer
interface

FOR SPONSORS

Global Sites, Consistent Execution

Access a high-performing network of locally led sites across North America and Europe, all supported by a centralized team and shared operational standards.

How We Deliver

Populace connects sites, data, and operations through one coordinated model, allowing feasibility, start-up, enrollment, and study management to move faster with fewer handoffs and greater consistency

Feasibility
  • Automated review workflows
  • Centralized protocol assessment
  • Trial-fit scoring across the network
Startup
  • Consolidated contracting across sites
  • Target 2-week budget/contract turnaround
  • One Populace PM for streamlined communication
Populace Health
Recruitment & Enrollment
  • Network-wide patient identification and referral pathways
  • Centralized outreach and indication-focused advertising
  • Prescreening and data-driven recruitment to improve conversion
Study Management
  • Ongoing trial monitoring and operational oversight
  • Real-time performance analytics and dashboards
  • Coordinated reporting across participating sites
The Result
Single Point of Accountability
Populace manages the operational complexity across the network so you can focus on study outcomes, not site-by-site logistics.
Consistent Results
A partner built for quality, speed, and transparency. We strengthen trial execution from start-up through close-out.
Connect with us

Capabilities Overview

Discover the capabilities of the Populace Network through our vast experience.

Therapeutic Areas

Allergy & Respiratory
Neurology & Psychiatry
Metabolic & Endocrine
Cardiology
Gastroenterology
Dermatology & Reconstructive
Rheumatology & Pain
Infectious Disease & Vaccines
Women’s Health & Urology

Specialized Support

Early Phase/Confinement:
On-site units for SAD/MAD, PK/PD sampling, and overnight monitoring

Biosimilars and Biologics:
Experience with immunogenicity testing, cold-chain handling, and specialized infusions

Medical Devices & Diagnostics:
Expertise in procedural support, imaging, and device usability studies

Hospital-Based/Acute Care:
Partnerships for inpatient, surgical, and psychiatric research

Decentralized & Remote Capabilities:
Sites conducting telehealth visits, home health integration, eConsent, and remote data capture

Types of Studies

Observational & Registry Studies
Interventional Trials
Long Term/Extension Studies
Devices, & Diagnostics
Decentralized & Hybrid trials
Gene Therapy

Specialty Populations

Fetal & Newborn
Geriatrics
Healthy Normal Subjects
Pediatrics & Adolescents

Our network site operational models:

Practice-embedded, hybrid, purpose built and community research sites all proposed and tailored to trial design capability and complexity.

01
Practice-Embedded Sites
02
Hybrid Sites
03
Purpose-Built Sites
04
Community Research Sites
Practice-Embedded Sites
Embedded in community, urgent care and specialty practices (or adjacent with patient data access)
EMR-informed patient identification and referral pathways
Familiar care setting supports engagement and retention
Strong fit when protocol needs align to a practice’s patient population
Hybrid Sites
Dedicated research team supporting start-up through close-out
Recruitment across 1 or more practices + purpose built site to expand reach
Indication based outreach to healthcare & research databases. Also includes advertising when needed.
Typical site, Research office is adjacent to the Doctors Office Next Door. Physicians and Research team see patients at the site or the practice.
Purpose-Built Sites
Dedicated research facilities designed for patient comfort and efficiency
Streamlined visit flow and study-ready infrastructure
Includes high powered ongoing digital advertising strategies
Community Research Sites
Research operates as a neighborhood location that can serve patients from multiple providers or self-referral
Patients come from broader community outreach, multiple referral sources, and local access, not primarily one clinic’s database
Each of our sites "engine” is access + convenience + broader recruitment reach

Global Research

With established capabilities across 4+ countries, we expand patient reach while maintaining consistent engagement and strong retention throughout the study.

United Kingdom
Romania
South Africa
Active market
Clinical site
Multiple site area

Dedicated to Diversity and Inclusion

Diversity is not a commitment we make, it is a standard we measure. Across the network, we track recruitment and enrollment demographics at the site and study level, so sponsors can see representation in real time and benchmark performance across the network.

Our approach is operational, not theoretical. We integrate inclusion into patient identification, referral pathways, and engagement strategies, ensuring diverse populations are not only reached but retained.

We don’t rely on isolated success stories. We deliver repeatable, data-driven diversity performance across a unified network of sites.

What this looks like in practice:

Brooklyn Clinical Research
55%
African American
Other populations
Pediatric & Adult Medicine
70%
Hispanic
African American
Core Healthcare
50%
Asian
Other populations
At scale
20K+
Active patients per site
10,000–20,000 on average across the network
4
Network performance metrics
Demographics · Referrals · Conversion · Retention
100%
Data-driven optimization
Measured, benchmarked, and continuously improved

Data Quality

Populace sites operate within a robust Quality Management System designed to build quality into every stage of study execution
[background image] image of a medical team collaborating (for a ai healthcare company)

Our teams follow consistent processes that support patient safety, protocol compliance, and reliable data integrity across the network.

In addition to sponsor audits, our sites routinely undergo regulatory inspections, including by the FDA, with a strong track record of successful outcomes. A dedicated internal quality team supports ongoing training, oversight, and continuous improvement to keep studies inspection-ready from start-up through close-out.

4+ Countries

supported through unified operations, expanding access with consistent execution.

200+ Sponsor Partners

trust us for reliable delivery, responsiveness, and quality.

600+ Studies Supported

across phases and indications, delivering experience that drives repeatable performance.

93% Patient Retention

driven by local access, patient-first scheduling, and proactive engagement.

Trusted by sponsors

Biogen
Merck
Bristol Myers Squibb
Pfizer
Novartis
Roche
MindMed
Cybin
Biogen
Merck
Bristol Myers Squibb
Pfizer
Novartis
Roche
MindMed
Cybin

What our partners are saying

"Populace Health was a key site network partner across multiple pain studies. Their sites consistently activated faster and enrolled at a higher rate than independent sites and other networks, which reduced delays and lowered our overall cost per randomized patient. Populace also streamlined site recommendations, contracting, and budget negotiations directly improving our timelines."

Clinical Operations Leader
Top 10 Global Biopharma Sponsor

"What differentiated Populace Health was the quality of their network site recommendations. Instead of simply listing availability, they provided specific, data-driven rationale with patient access, historical enrollment performance, and operational readiness so we could make faster, higher-confidence selections. Their enrollment forecasts were grounded in prior study data, and their sites came prepared, which reduced back-and-forth and accelerated start-up."

Director of Clinical Operations,
Global CRO
image of job applicants in a discussion at a medical clinic

Case Study Snapshot:

A Phase 3 psoriasis study was struggling with high screen-fail rates while trying to accelerate enrollment. Populace added 5 dermatology research sites and implemented targeted prescreening workflows to improve patient fit before formal screening, resulting in 40% fewer screen failures and a 42% increase in patient randomizations.